Bio-path Holdings, Inc.

BIO-PATH HOLDINGS, INC. exhibits a severely distressed capital structure, reporting negative total equity of $-8.49 million against total liabilities of $9.16 million as of Q1 2026. The balance sheet shows zero cash and equivalents, resulting in a current ratio of 0.07, which indicates an immediate inability to meet short-term obligations. Operating cash flow is negative at $-38,000, further depleting liquidity reserves. The market capitalization stands at approximately $355,000, reflecting a market price of $0.038 per share. The debt-to-equity ratio is reported as -0.0 due to the negative equity base, rendering traditional leverage metrics less informative than the absolute liability levels.

Profitability metrics are deeply negative, with a return on assets of -39.88% and a nominal return on equity of 3.18%, which is distorted by the negative equity denominator. The company reported an operating income of $-297,000 and a net income of $-270,000 for the period. Without cohort median data for direct comparison, these figures indicate a pre-revenue or early-stage clinical profile where expenses significantly outpace any generated income. The absence of revenue, confirmed by analyst estimates of $0.00, underscores the company's reliance on capital markets for funding rather than operational cash generation.

Segment and geographic data are not explicitly detailed in the provided financial snapshot, but the company's activity is broadly classified under Pharmaceuticals. The lack of revenue suggests that any potential product lines or services have not yet achieved commercial scale. The company's operations appear concentrated in its core pharmaceutical development activities, with no diversified revenue streams evident from the available data.

Growth trajectory is characterized by a lack of revenue generation and persistent losses. Historical periods data is not provided in the input, but the current financial snapshot shows a continuation of negative operating income and net income. The company's share count remains relatively stable at approximately 9.34 million basic shares, with diluted shares at 9.34 million, indicating limited recent dilution from options or warrants in the immediate period, although historical filings reference multiple offerings.

Risk factors are elevated, with high liquidity risk and medium dilution risk identified. Key flags include current liabilities exceeding current assets, filings referencing going-concern or substantial-doubt language, and source documents mentioning dilution or offering risk. The company has explicitly stated that its available cash will not be sufficient to fund liquidity and capital expenditure requirements for the next 12 months, raising substantial doubt about its ability to continue as a going concern.

Recent events include an 8-K filing with material items 3.02 and 5.03, indicating changes in financial statements or other corporate governance matters. The company also conducted a Tier 1 Regulation A offering, selling 466,100 shares for proceeds of $13,983 in April 2026. Filings reference warrant liabilities from previous registered direct offerings in 2023 and 2024, highlighting the complex capital structure and potential for future dilution.

Operating income -$297.0k.

• ▍Operating income -$297.0k

Operating income -$8.3M.

• ▍Operating income -$8.3M

Operating income -$12.0M.

• ▍Operating income -$12.0M

Operating income -$15.8M.

• ▍Operating income -$15.8M

Operating income -$15.8M.

• ▍Operating income -$15.8M

Operating income -$13.9M.

• ▍Operating income -$13.9M

Operating income -$13.9M.

• ▍Operating income -$13.9M